バンコミシンに関連した腎臓毒性に対するジレウトンの保護機構の探索
Cole S Hudson1, James E Smith2, Rongjin Sun1
1Department of Pharmacological & Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, TX 77204, United States.
Toxicology and applied pharmacology
|September 6, 2025
まとめ
ジレウトンは,酸化ストレスを軽減し,近接管細胞のHO-1レベルを維持することによって,バンコマイシン誘発性腎臓損傷から保護することができます. この発見は,薬剤耐性感染症のバンコミシン使用を改善する可能性がある.
科学分野:
- 薬理学について
- 腎臓科
- 毒理学について
背景:
- バンコミシンは抵抗性感染症の治療に不可欠ですが,腎臓毒性を引き起こします.
- ヴァンコマイシン関連腎臓損傷を遅らせる可能性を示した.
研究 の 目的:
- バンコミシン誘発性腎臓毒性に対するジレウトンの保護メカニズムを解明する.
- 腎臓細胞における酸化ストレスと特定の細胞経路に対するジレウトンの影響を研究する.
主な方法:
- ヴァンコマイシンとジレウトンを投与したネズミは,腎臓損傷と血清のクレアチニンを評価した.
- ヴァンコマイシンとジレウトンに曝された近接管状細胞を in vitro 試験で使用した.
- 細胞の活力,バンコミシン蓄積,活性酸素種 (ROS),およびタンパク質濃度が評価された.
主要な成果:
- バンコミシンは腎臓に重大な損傷を与え,血清のクレアチニンが上昇した.
- ヴァンコマイシンの薬理学に影響を与えることなく,Zileutonは腎臓の損傷とクレアチニンのレベルを軽減しました.
- In vitroでは,ジレウトンはバンコミシンによる細胞損傷を軽減し,ROSを減少させ,HO-1レベルを回復させた.
結論:
- ジレウトンはバンコマイシンの腎毒性に対する保護効果を示しています.
- 潜在的なメカニズムは,近接管細胞における酸化ストレスとHO-1レベルを削減することを含む.
- ヴァンコマイシン治療の強化のためのジレウトンの臨床使用は,さらなる研究によって支持される可能性がある.
さらに関連する動画
関連する概念動画
Drug Elimination by Renal Route: Tubular Secretion
2.5K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.5K
Drug Elimination by Renal Route: Tubular Reabsorption
3.9K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.9K
Antihypertensive Drugs: Thiazide-Class Diuretics
859
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
859
Antiasthma Drugs: Leukotriene Modifiers
453
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
453
Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321


